Short-term Evaluation of Motor and Sensory Function in Post-COVID-19 Patients

Coronavirus disease 19 (COVID-19) can cause neuropsychiatric, psychological and psychosocial impairments. Literature regarding the sensory and motor affection of COVID-19 is still limited.

Public health emergencies as COVID-19 are likely to cause adverse neuropsychiatric impacts. Cognitive impairments after SARS-COV-2 infection were noticed, COVID-19 patients complain of poor concentration, declined memory, and insomnia, as well as anxiety and depression symptoms.

in a study; Neurological manifestations described in 36.4% of 214 patients with confirmed COVID-19. However, the symptoms described [dizziness (not further defined), headache, and impaired consciousness] are commonplace in many severe infections and represent disturbances in neurological function rather than a neurological disease per se. Anosmia and ageusia have received much attention, but are ubiquitous in other common upper respiratory tract infections. While a reported increased risk of cerebrovascular disease.

Inclusion criteria

• Patients with confirmed RT-PCR COVID-19 infection with mild to moderate severity based on the Egyptian ministry of health (MOH) protocol (version 1.4, November 2020) with neurological symptoms suggestive of peripheral neuropathy

Exclusion criteria

• patients presenting with neurological manifestations other than peripheral neuropathy, such as stroke, cerebral hemorrhage, encephalitis, or meningitis.
• Patients with any medical condition or comorbidities that may affect the result of the study as diabetes, arthritis, and carpel tunnel syndrome.
• Severe COVID-19 patients with a critical condition that needs hospitalization and ventilatory support were also excluded from the study.